Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), announced that an article entitled "Pivotal Trial with Plant-Cell-Expressed Recombinant Glucocerebrosidase, taliglucerase alfa, a Novel Enzyme Replacement Therapy for Gaucher Disease" has been published in Blood, the Journal of the...
Talecris Biotherapeutics, Inc. (Nasdaq: TLCR) announced the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults...
Talecris Biotherapeutics (Nasdaq: TLCR) announced the publication of results from a study showing that PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN® (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 protein in patients with...
GTC Biotherapeutics, Inc. ("GTC", OTCBB: GTCB.OB) announced today that it has signed a definitive agreement whereby the Company has regained US commercialization rights to ATryn from Lundbeck, Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen Stock Exchange: LUN)...
BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, announced today the introduction of SecuriVAX(SM) (http://www.securivax.com), an online supply solution providing the healthcare community a one-stop source for a wide variety of vaccines. As a result of its...
BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, announced today the introduction of SecuriVAX(SM) (http://www.securivax.com), an online supply solution providing the healthcare community a one-stop source for a wide variety of vaccines. As a result of its...
BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, announced today the introduction of SecuriVAX(SM) (http://www.securivax.com), an online supply solution providing the healthcare community a one-stop source for a wide variety of vaccines. As a result of its...
BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, announced today the introduction of SecuriVAX(SM) (http://www.securivax.com), an online supply solution providing the healthcare community a one-stop source for a wide variety of vaccines. As a result of its...
BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, announced today the introduction of SecuriVAX(SM) (http://www.securivax.com), an online supply solution providing the healthcare community a one-stop source for a wide variety of vaccines. As a result of its...
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC)...
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC)...